These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33706624)

  • 1. Desvenlafaxine in the treatment of major depression: an updated overview.
    Norman TR; Olver JS
    Expert Opin Pharmacother; 2021 Jun; 22(9):1087-1097. PubMed ID: 33706624
    [No Abstract]   [Full Text] [Related]  

  • 2. Desvenlafaxine for the treatment of major depressive disorder.
    Kornstein SG; McIntyre RS; Thase ME; Boucher M
    Expert Opin Pharmacother; 2014 Jul; 15(10):1449-63. PubMed ID: 24914479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
    Perry R; Cassagnol M
    Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.
    Liebowitz MR; Manley AL; Padmanabhan SK; Ganguly R; Tummala R; Tourian KA
    Curr Med Res Opin; 2008 Jul; 24(7):1877-90. PubMed ID: 18507895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.
    Carrasco JL; Kornstein SG; McIntyre RS; Fayyad R; Prieto R; Salas M; Mackell J; Boucher M
    Int Clin Psychopharmacol; 2016 May; 31(3):134-46. PubMed ID: 26895080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
    DeMartinis NA; Yeung PP; Entsuah R; Manley AL
    J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.
    Atkinson S; Lubaczewski S; Ramaker S; England RD; Wajsbrot DB; Abbas R; Findling RL
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):55-65. PubMed ID: 29185786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
    Atkinson S; Thurman L; Ramaker S; Buckley G; Jones SR; England R; Wajsbrot D
    CNS Spectr; 2019 Oct; 24(5):496-506. PubMed ID: 30419989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
    Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
    Endicott J; Lam RW; Hsu MA; Fayyad R; Boucher M; Guico-Pabia CJ
    J Affect Disord; 2014 Sep; 166():307-14. PubMed ID: 25012446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.
    Findling RL; Groark J; Chiles D; Ramaker S; Yang L; Tourian KA
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):201-9. PubMed ID: 24611442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
    Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
    J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.
    Katzman MA; Nierenberg AA; Wajsbrot DB; Meier E; Prieto R; Pappadopulos E; Mackell J; Boucher M
    J Clin Psychopharmacol; 2017 Oct; 37(5):555-561. PubMed ID: 28817491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.